De Novo Minimal Change Disease After Acute Rejection in a Kidney Transplant Recipient with an APOL1 Risk Allele (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1167; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "He received basiliximab induction (cPRA 0%, HLA mismatch 1-2-1)...The patient received Methylprednisolone 500 mg IV x 3 doses, followed by a protracted course of Prednisone taper...CNI optimization and cautious rituximab represent potential TCMR treatment options post-infection clearance. APOL1 genotyping may improve transplant risk stratification. Fig 1: Pre and Post-transplant creatinine and proteinuria trends."
Clinical • Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Hepatitis C • Hypertension • Immunology • Infectious Disease • Nephrology • Respiratory Diseases • Transplant Rejection • Transplantation
|
|
Geethika Earthineni; Maria Aurora C. Posadas; Ahmed I. Kamal Abdelkader; Munsef Barakat; Sherida Edding; Vishwajeeth Pasham; Blaithin A. McMahon; Sakshi Vaishnav
|